title: Terlipressin for catecholamine-resistant septic shock in children.
abstract: OBJECTIVE
  To report the effects of terlipressin treatment in four paediatric patients with catecholamine-resistant hypotensive septic shock.
  
  
  METHODS
  Case report in the pediatric intensive care unit of a university hospital.
  
  
  METHODS
  Four children with severe septic shock and hypotension resistant to high doses of norepinephrine and other cathecolamines.
  
  
  METHODS
  Terlipressin was added to the standard treatment, by intravenous bolus at a dose of 0.02 mg/kg every 4 h during a maximum time of 3 days.
  
  
  RESULTS
  In all cases, terlipressin induced a rapid and sustained improvement in mean arterial pressure, which allowed the lessening or even withdrawal of norepinephrine infusion. No related adverse effects were detected.
  
  
  CONCLUSIONS
  Terlipressin might be considered, at least as a rescue therapy, for hypotension resistant to catecholamines in children with septic shock. Further studies are needed to confirm the beneficial effects found in our patients. The optimal administration schedule remains to be elucidated.
authors.affiliation: Pediatric Emergency and Critical Care Division, Department of Pediatrics, Hospital Clínico Universitario de Santiago de Compostela, Choupana s/n, 15706 Santiago de Compostela, Spain, Antonio.Rodriguez.Nunez@sergas.es
authors.forename: Antonio
authors.initials: A
authors.lastname: Rodríguez-Núñez
authors.forename: Manuel
authors.initials: M
authors.lastname: Fernández-Sanmartín
authors.forename: Federico
authors.initials: F
authors.lastname: Martinón-Torres
authors.forename: Natalia
authors.initials: N
authors.lastname: González-Alonso
authors.forename: José María
authors.initials: JM
authors.lastname: Martinón-Sánchez
mesh_terms: D002395:Catecholamines / Q000008:administration & dosage / Q000494:pharmacology; D002648:Child; D002675:Child, Preschool; D004351:Drug Resistance; D006801:Humans; D007022:Hypotension / Q000188:drug therapy* / Q000209:etiology; D007223:Infant; D007262:Infusions, Intravenous; D008236:Lypressin / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D008297:Male; D012772:Shock, Septic / Q000150:complications / Q000188:drug therapy*; D000077585:Terlipressin; D014662:Vasoconstrictor Agents / Q000627:therapeutic use*
chemical_list: D002395:Catecholamines; D014662:Vasoconstrictor Agents; D008236:Lypressin; D000077585:Terlipressin